6505--Subcutaneous Anti-Interleukin Monoclonal Antibodies for Asthma (VA-21-00000590)
Closed Solicitation Posted
This opportunity was awarded. See the award notice from .
- Solicitation number
- 36E79720R0068
- Agency
-
National Acquisition Center
Headquarters, Department of Veterans Affairs
- Responses due
- Set-aside
- No set-aside
Opportunity facts
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
Notice details come from SAM.gov. Updated .
About this opportunity
The Department of Veterans Affairs National Acquisition Center intends to award an unrestricted contract to provide subcutaneous anti-interleukin monoclonal antibodies for asthma treatment. The solicitation seeks a contractor to supply mepolizumab, dupilumab, and benralizumab to an estimated 4,650 patients annually across the VA, DoD, Bureau of Prisons, and Indian Health Service through the VA and DOD pharmaceutical prime vendor programs. The contract period is one base year with four one-year option periods. Offerors must include packaging, labeling, and unique NDC identifiers meeting FDA standards. The solicitation number is 36E79720R0068 and will close on September 30, 2020, with the NAICS code 325412.
There is no set-aside designation for this procurement. The estimated annual patient populations are 3,880 patients within the VA, 552 patients within the DoD, 18 patients within the BOP, and 200 patients within IHS. Offerors must provide pricing for the monoclonal antibody products in various dosages and treatments. Distribution will occur through the VA and DOD pharmaceutical prime vendor programs to treat patients at locations serviced by those agencies.
Notice text
PRE-SOLICITATION NOTICE: The VA National Acquisition Center intends to issue Request for Proposal (RFP) 36E79720R0068 for an unrestrictive procurement for Anti-Interleukin Monoclonal Antibodies for Asthma, for the Department of Veterans Affairs (VA), Department of Defense (DOD), Bureau of Prisons (BOP), and Indian Health Service (IHS). The VA will award one contract to the responsible offeror who will be able to provide an uninterrupted source of supply for the contracted items. The contract period will be for one year plus four pre-priced one-year option periods. The contract items will be distributed through the VA s and DOD s respective Pharmaceutical Prime Vendor Programs. Offerors must state the exact name (name that appears on label) by which the antibodies will be supplied and have a unique NDC number. Solicitation #36E79720R0068 will be electronically issued in commercial item format in accordance with FAR Part 12 on or about September 16, 2020, with a tentative closing date of September 30, 2020. The NAICS code for this procurement is 325412. Any future amendments and other miscellaneous documents will be available electronically for download at the following URL: http://www.fedbizopps.gov. No paper copies of the solicitation will be available, and no telephone requests for paper copies of the solicitation will be accepted. Interested offerors are advised to continuously check this URL for any changes to this solicitation. All responsible sources may submit an offer that if timely received, will be considered. The point of contact for this procurement is Chris Carthron. Questions can be e-mailed to: Christopher.Carthron@va.gov.
The estimated annual requirements are as follows:
ITEM
Packages
DESCRIPTION
Dosing
Doses/Year
1a
1
MEPOLIZUMAB 100MG/VIL INJ
100mg Q 4 weeks
13
1b
1
MEPOLIZUMAB 100MG/ML,AUTO INJCT
100mg Q 4 weeks
13
1c
1
MEPOLIZUMAB 100MG/ML,SYRINGE
100mg Q 4 weeks
13
OR
OR
OR
OR
OR
2a
1
DUPILUMAB 150MG/ML INJ,SYR,2ML 2 SYRINGES PER PACK
400-600mg loading dose then 200mg or 300mg every other week
13 packs of 2, or 26 syringes
2b
1
DUPILUMAB 200MG/1.14ML INJ,SYR 2 SYRINGE PER PCK
400-600mg loading dose then 200mg or 300mg every other week
26
OR
OR
OR
OR
OR
3a
1
BENRALIZUMAB 30MG/ML INJ,SYR,1ML
30mg Q 4 weeks x 3 doses then Q 8 weeks
6.5
3b
1
BENRALIZUMAB 30MG/ML INJ,PEN,1ML
30mg Q 4 weeks x 3 doses then Q 8 weeks
6.5
Agency
Number of Patients For Respiratory Use Only
VA
3,880
DoD
552
BOP
18
IHS
200
Total Estimated Patients Annually 4,650
Files
| File | Type | Posted |
|---|---|---|
| 36E79720R0068 0001.docx | DOCX document | |
| 36E79720R0068.docx | DOCX document |
Notice history
| Notice | Type | Posted |
|---|---|---|
| 6505--Subcutaneous Anti-Interleukin Monoclonal Antibodies for Asthma/Benralizumab | Award Notice | |
| This notice | Solicitation | |
| 6505--Subcutaneous Anti-Interleukin Monoclonal Antibodies for Asthma (VA-21-00000590) | Pre-Solicitation |
Similar open opportunities
| Opportunity | Agency | Set-aside | Responses due |
|---|---|---|---|
| Epinephrine Injector | Medical Supply Chain | No set-aside | |
| 6505--FY27 Lenalidomide BPA | Veterans Integrated Service Network 22 | No set-aside |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity